Valneva SE Sponsored ADR VALN 深 沪
已收盘 02-06 16:00:00 美东时间
9.49
+0.160
+1.71%
华盛通- 最 高9.63
- 今 开9.44
- 成交量 4.75万股
- 最 低 9.35
- 昨 收 9.33
- 总市值 8.23亿
- 52周最高 12.25
- 市盈率 静 --
- 换手率 0.05%
- 52周最低 5.4289
- 委 比 53.05%
- 总股本 8670.77万
- 历史最高 67.84
- 量 比 4.46
- 振 幅 3.00%
- 历史最低 3.62
- 每 手 1
- 风险率 1.62%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Valneva Steps Back From US Approval Bid For Chikungunya Vaccine
Valneva withdraws U.S. applications for its chikungunya vaccine Ixchiq after the FDA suspended the license and placed studies on hold following new reports of serious adverse events.
01-21 04:58
Valneva, Tesla And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around...
01-20 21:05
Valneva And Serum Institute Mutually Terminate Chikungunya Vaccine License; Valneva Regains Full Control To Accelerate Access In High-Risk Countries
Valneva SE ("Valneva" or "the Company"), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company today announced that they have mutually agreed to discontinue their license
01-01 00:47
Valneva Announces Strategic Consolidation of French Operations
Valneva ( ($VALN) ) has shared an update. On November 26, 2025, Valneva SE anno...
2025-11-28 19:57
Valneva Plans To Close Facilities In Nantes, France, To Consolidate Operations At Lyon Site
Valneva SE (NASDAQ:VALN, PARIS:VLA) today announced a strategic initiative to optimize its organizational footprint in France as part of the Company's ongoing efforts
2025-11-27 00:31
快讯 | Valneva SE - 辉瑞计划于2026年向美国食品药品监督管理局（FDA）提交生物制品许可申请，并向欧洲药品管理局（EMA）提交上市授权申请（MAA）。
Valneva SE - Pfizer Aims to Submit a Biologics License Application to U.S. FDA ...
2025-11-26 14:02
Valneva Announces Positive Final Phase 2 Results for Lyme Disease Vaccine Candidate
Antibody levels remained well above baseline across all six serotypes and age g...
2025-11-26 14:00
Valneva Q3 EPS $(0.61) Misses $(0.30) Estimate, Sales $34.386M Miss $50.250M Estimate
Valneva (NASDAQ:VALN) reported quarterly losses of $(0.61) per share which missed the analyst consensus estimate of $(0.30) by 103.33 percent. This is a 306.67 percent decrease over losses of $(0.15) per share from the
2025-11-21 06:26
Valneva SE reports Q3 results
Valneva SE press release (OTCPK:INRLF): 9M Revenue of €127M. Cash and cash equivalents of €143.5 million at end of September 2025 More on Valneva Valneva Outlook: Safety Blow To Ixchiq And Valuation C...
2025-11-20 19:10
First locally-acquired chikungunya case reported in U.S. since 2019
A person in Nassau County, New York, has tested positive for the chikungunya virus, a case state health officials confirmed as the first locally acquired incidence of the mosquito-borne disease in the...
2025-10-16 01:46
